))
Turning Drugs Into Vaccines to Offer Longer-Term Protection Against Malaria
Manage episode 386124461 series 3531530
内容由Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health提供。所有播客内容（包括剧集、图形和播客描述）均由 Johns Hopkins Malaria Research Institute and Johns Hopkins Bloomberg School of Public Health 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
How ‘chemical vaccines’ could offer long-term protection against malaria in endemic areas, and combat the problems of dosing and drug resistance.
Transcript
Drugs used to prevent and treat malaria are vital tools in the malaria toolkit – but they aren’t perfect. When used to prevent malaria, people must remember to take them regularly, or they won’t be as effective. And when they’re used to treat the disease, the sheer scale of infection – with billions of parasites in the body – makes it likely that some of those parasites will be drug-resistant, leading to treatment failure. But, when you formulate the drugs differently, as nano-particles in a water-based solution, and inject them, like a vaccine, those same drugs can offer effective, long-lasting protection against the disease. This so-called ‘chemical vaccine’, based on the antimalarial drug atovaquone, has been shown in mice to effectively stop the infection and subsequently, the onward transmission of the parasites to mosquitoes. The long-term hope is that a single dose of the ‘chemical vaccine’ could offer long-term protection against malaria in endemic areas, and help combat the problems of dosing and drug resistance.
Source
Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito
About The Podcast
The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.
64集单集
分享
